Cargando…

Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action

A highly expressed prostaglandin E(2) (PGE(2)) in tumor tissues suppresses antitumor immunity in the tumor microenvironment (TME) and causes tumor immune evasion leading to disease progression. In animal studies, selective inhibition of the prostaglandin E receptor 4 (EP4), one of four PGE(2) recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Take, Yukinori, Koizumi, Shinichi, Nagahisa, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076081/ https://www.ncbi.nlm.nih.gov/pubmed/32210957 http://dx.doi.org/10.3389/fimmu.2020.00324

Ejemplares similares

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE(2)-mediated immunosuppression and inhibits breast cancer metastasis
por: Ma, Xinrong, et al.
Publicado: (2013)

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
por: Kundu, Namita, et al.
Publicado: (2013)

Eicosanoids in Cancer: Prostaglandin E(2) Receptor 4 in Cancer Therapeutics and Immunotherapy
por: Ching, Mc Millan, et al.
Publicado: (2020)

A selective antagonist of prostaglandin E receptor subtype 4 attenuates abdominal aortic aneurysm
por: Mamun, Al, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4
por: van Geffen, Chiel, et al.
Publicado: (2021)

Prostaglandin E2 Antagonizes TGF-β Actions During the Differentiation of Monocytes Into Dendritic Cells
por: Remes Lenicov, Federico, et al.
Publicado: (2018)

Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro
por: Sorrin, Aaron J., et al.
Publicado: (2021)

Characterization of the Signaling Modalities of Prostaglandin E2 Receptors EP2 and EP4 Reveals Crosstalk and a Role for Microtubules
por: Vleeshouwers, Ward, et al.
Publicado: (2021)

Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor
por: Carlson, Noel G, et al.
Publicado: (2009)

A novel prostaglandin E receptor 4 (EP4) small molecule antagonist induces articular cartilage regeneration
por: Jin, Yunyun, et al.
Publicado: (2022)

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
por: Awasthi, Shanjana
Publicado: (2014)

Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation
por: Kirkby Shaw, Kristin, et al.
Publicado: (2015)

LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles
por: Jin, Yan, et al.
Publicado: (2017)

The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin Sensitivity
por: Yasui, Mika, et al.
Publicado: (2015)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

AMG853, A Bispecific Prostaglandin D(2) Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like Nephritis Activity in Lyn-Deficient Mice
por: Pellefigues, Christophe, et al.
Publicado: (2022)

Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming
por: Muraoka, Naoto, et al.
Publicado: (2019)

Prostaglandin E(2) receptor EP4 regulates cell migration through Orai1
por: Osawa, Kohei, et al.
Publicado: (2019)

The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases
por: Shepard, Ella R., et al.
Publicado: (2021)

Adenosine and Prostaglandin E(2) Production by Human Inducible Regulatory T Cells in Health and Disease
por: Whiteside, Theresa L., et al.
Publicado: (2013)

Hypoxia Induces Macrophage tnfa Expression via Cyclooxygenase and Prostaglandin E2 in vivo
por: Lewis, Amy, et al.
Publicado: (2019)

Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis
por: Chang, Jian, et al.
Publicado: (2015)

Prostaglandin E(2) Inhibits Group 2 Innate Lymphoid Cell Activation and Allergic Airway Inflammation Through E-Prostanoid 4-Cyclic Adenosine Monophosphate Signaling
por: Zhou, Yu, et al.
Publicado: (2018)

Identification of Francisella novicida mutants that fail to induce prostaglandin E(2) synthesis by infected macrophages
por: Woolard, Matthew D., et al.
Publicado: (2013)

Human Oral Epithelial Cells Suppress T Cell Function via Prostaglandin E2 Secretion
por: Sanchez-Trincado, Jose L., et al.
Publicado: (2022)

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
por: Sasikumar, Pottayil G., et al.
Publicado: (2022)

Molecules and Prostaglandins Related to Embryo Tolerance
por: Mayoral Andrade, Gabriel, et al.
Publicado: (2020)

A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis
por: He, Jiacheng, et al.
Publicado: (2022)

Prostaglandin E2 Stimulates the Expansion of Regulatory Hematopoietic Stem and Progenitor Cells in Type 1 Diabetes
por: Ben Nasr, Moufida, et al.
Publicado: (2018)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy
por: Soon, Chai Fen, et al.
Publicado: (2019)

The pharmacological effect of BGC20-1531, a novel prostanoid EP(4) receptor antagonist, in the Prostaglandin E(2) human model of headache
por: Antonova, Maria, et al.
Publicado: (2011)

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab
por: Davies, Anna M., et al.
Publicado: (2017)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
por: Mollica Poeta, Valeria, et al.
Publicado: (2019)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Marek’s Disease Virus Modulates T Cell Proliferation via Activation of Cyclooxygenase 2-Dependent Prostaglandin E2
por: Kamble, Nitin, et al.
Publicado: (2021)

Steroidal Antagonists of Progesterone- and Prostaglandin E(1)-Induced Activation of the Cation Channel of Sperm
por: Carlson, Erick J., et al.
Publicado: (2022)

PPARγ as an E3 Ubiquitin-Ligase Impedes Phosphate-Stat6 Stability and Promotes Prostaglandins E(2)-Mediated Inhibition of IgE Production in Asthma
por: Wu, Jia, et al.
Publicado: (2020)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7b0k3bvcibs6d6palhbjjai0lu